ArticleInterdisciplinary cardiovascular and thoracic surgery2026
The Ross Operation in Children-What Is the Long-Term Fate of the Autograft?
Article in Interdisciplinary cardiovascular and thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe Ross operation achieves excellent outcomes in children and adolescents, but the influence of age at surgery and underlying pathology on long-term results remains uncertain. Evidence on autograft dilatation necessitating reintervention is also limited. This study aimed to identify patient groups best served from the Ross procedure and to evaluate long-term autograft performance.
methodsAll consecutive patients <18 years undergoing a Ross or Ross-Konno procedure between 1991 and 2024 at a single centre were analysed. Demographic, operative, and follow-up data were collected. Patients were stratified into age groups (neonate, infant, child, adolescent) and diagnostic groups (isolated aortic valve disease, aortic stenosis with subaortic stenosis, Shone's complex, and complex congenital heart disease [CHD]). Outcomes included overall survival, freedom from autograft and right ventricle-pulmonary artery (RV-PA) conduit reintervention, and severe autograft dilatation (>50 mm or >25 mm/m2).
resultsA total of 226 patients underwent surgery at a median age of 8.5 years; 67% were male. Median follow-up was 9.5 years (IQR 12.7). Operative mortality was 2% and overall mortality 5%. Survival exceeded 90% at 30 years in all groups except neonates (60% at 5 years). After adjustment for age, Shone's complex and complex CHD were associated with an 11-fold and 8.8-fold increased hazard of death, respectively (P < .03). Freedom from autograft reintervention was 82% and from RV-PA conduit reintervention was 66% at 25 years. Freedom from severe autograft dilatation was 71% at 20 years by absolute dimension and 54% when indexed to BSA. Greater than mild aortic regurgitation at discharge conferred a 17-fold risk of autograft intervention (P < .001).
conclusionsThe Ross procedure provides excellent long-term survival and valve durability in children and adolescents, particularly those with isolated aortic valve disease. Autograft dilatation and conduit reintervention remain important late risks, reinforcing the need for lifelong surveillance in specialised centres.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.